UY30394A1 - Composiciones farmacéuticas estabilizadas que comprenden fesoterodina - Google Patents

Composiciones farmacéuticas estabilizadas que comprenden fesoterodina

Info

Publication number
UY30394A1
UY30394A1 UY30394A UY30394A UY30394A1 UY 30394 A1 UY30394 A1 UY 30394A1 UY 30394 A UY30394 A UY 30394A UY 30394 A UY30394 A UY 30394A UY 30394 A1 UY30394 A1 UY 30394A1
Authority
UY
Uruguay
Prior art keywords
pharmaceutical compositions
stabilized pharmaceutical
fesoterodine
include fesoterodine
stabilized
Prior art date
Application number
UY30394A
Other languages
English (en)
Inventor
Irngartinger Meike
Bicane Fatima
Paulus Kerstin
Komenda Michael
Mika Hans-Joergen
Arth Christoph
Hans Lindner
Original Assignee
Sanol Arznei Schwarz Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38521333&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY30394(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanol Arznei Schwarz Gmbh filed Critical Sanol Arznei Schwarz Gmbh
Publication of UY30394A1 publication Critical patent/UY30394A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente solicitud se refiere a una composicion farmacéutica que comprende fesoteradina o su sal o solvato farmacéuticamente aceptable y un estabilizante seleccionado entre el grupo que comprende xilito, sorbitol, polidextrosa, isomalta y dextrosa.
UY30394A 2006-06-09 2007-06-06 Composiciones farmacéuticas estabilizadas que comprenden fesoterodina UY30394A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06011941 2006-06-09
EP06011942 2006-06-09
EP06011943 2006-06-09

Publications (1)

Publication Number Publication Date
UY30394A1 true UY30394A1 (es) 2007-11-30

Family

ID=38521333

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30394A UY30394A1 (es) 2006-06-09 2007-06-06 Composiciones farmacéuticas estabilizadas que comprenden fesoterodina

Country Status (38)

Country Link
EP (1) EP2029134B1 (es)
JP (2) JP4743321B2 (es)
KR (1) KR101316773B1 (es)
CN (1) CN101466371B (es)
AP (1) AP2416A (es)
AR (1) AR061289A1 (es)
AT (1) ATE517619T1 (es)
AU (1) AU2007255408B2 (es)
BR (1) BRPI0712865B1 (es)
CA (1) CA2652712C (es)
CR (1) CR10494A (es)
CU (1) CU23850B1 (es)
CY (1) CY1111934T1 (es)
DK (1) DK2029134T3 (es)
EA (1) EA015909B9 (es)
EC (1) ECSP089010A (es)
ES (1) ES2370943T3 (es)
GT (1) GT200800276A (es)
HK (1) HK1128626A1 (es)
HR (1) HRP20110776T1 (es)
IL (2) IL195732A (es)
MA (1) MA30504B1 (es)
MX (1) MX2008015736A (es)
MY (1) MY146574A (es)
NI (1) NI200800318A (es)
NL (1) NL2000690C2 (es)
NO (1) NO341980B1 (es)
NZ (1) NZ572616A (es)
PE (2) PE20120476A1 (es)
PL (1) PL2029134T3 (es)
PT (1) PT2029134E (es)
RS (1) RS51973B (es)
SI (1) SI2029134T1 (es)
TN (1) TNSN08505A1 (es)
TW (2) TWI397409B (es)
UY (1) UY30394A1 (es)
WO (1) WO2007141298A1 (es)
ZA (1) ZA200806411B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2294047A2 (en) * 2008-04-04 2011-03-16 Actavis Group PTC EHF Novel mandelate salt of fesoterodine
IT1392082B1 (it) 2008-12-10 2012-02-09 Chemi Spa Nuove forme solide della fesoterodina fumarato
MX2011011937A (es) 2009-05-11 2012-01-27 Ratiopharm Gmbh Desfesoterodina en la forma de una sal del acido tartarico.
EP2316432A1 (de) 2009-10-30 2011-05-04 ratiopharm GmbH Zusammensetzung enthaltend Fesoterodin und Ballaststoffe
US20130172411A1 (en) * 2010-03-22 2013-07-04 Cadila Healthcare Limited Stable pharmaceutical compositions comprising fesoterodine
TWI590821B (zh) 2011-01-18 2017-07-11 輝瑞有限公司 固體分子分散液
EP2508175A1 (en) 2011-04-08 2012-10-10 LEK Pharmaceuticals d.d. Pharmaceutical composition comprising fesoterodine or a salt or a solvate thereof
EP2508173A1 (en) 2011-04-08 2012-10-10 LEK Pharmaceuticals d.d. Stabilized pharmaceutical composition comprising fesoterodine
WO2013054337A1 (en) * 2011-07-04 2013-04-18 Cadila Healthcare Limited Extended release pharmaceutical compositions of fesoterodine
WO2013046194A2 (en) * 2012-05-18 2013-04-04 Alembic Pharmaceuticals Limited The novel reference markers for fesoterodine fumarate
ES2674811T3 (es) * 2012-07-02 2018-07-04 Hetero Research Foundation Composiciones estables de fesoterodina
CN108721265B (zh) 2012-11-02 2022-12-02 默里和普尔企业有限公司 通过给予秋水仙碱衍生物治疗或预防心血管事件
CN105307643A (zh) 2013-04-16 2016-02-03 默里和普尔企业有限公司 秋水仙碱的缓释制剂及其使用方法
CZ2014400A3 (cs) 2014-06-09 2015-12-16 Zentiva, K.S. Stabilizovaná formulace fesoterodinu
CN105687154A (zh) * 2014-11-27 2016-06-22 合肥信风科技开发有限公司 含非索罗定的药用组合物及其制备方法
WO2019011393A1 (en) 2017-07-12 2019-01-17 Rontis Hellas S.A. EXTENDED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING FESOTERODINE AND PREPARATION METHOD THEREOF
WO2019132832A1 (en) * 2017-12-25 2019-07-04 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Tablet compositions of fesoterodine fumarate
TR201721437A2 (tr) * 2017-12-25 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Fesoterodi̇ni̇n modi̇fi̇ye salim sağlayan formülasyonlari
KR102018495B1 (ko) * 2018-03-13 2019-09-05 충북대학교 산학협력단 과민성 방광의 치료를 위한 서방형의 이중층 정제 및 이의 제조방법
WO2019206391A1 (en) 2018-04-26 2019-10-31 Rontis Hellas S.A. Extended release pharmaceutical composition containing fesoterodine and process for the preparation thereof
CN110151720B (zh) * 2019-05-09 2019-12-17 合肥信风科技开发有限公司 含非索罗定的药用组合物及其制备方法
WO2023145486A1 (ja) * 2022-01-28 2023-08-03 沢井製薬株式会社 フェソテロジンフマル酸塩含有製剤の製造方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002505282A (ja) * 1998-03-03 2002-02-19 塩野義製薬株式会社 ホスホリパーゼ阻害剤の［［３−（２−アミノ−１，２−ジオキソエチル）−２−エチル−１−フェニルメチル）−１ｈ−インドール−４−イル］オキシ］酢酸ナトリウムを含む薬学的組成物
EP0957073A1 (en) 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
DE29923134U1 (de) * 1999-11-16 2000-06-29 Sanol Arznei Schwarz Gmbh Stabile Salze neuartiger Derviate von 3,3-Diphenylpropylaminen
DE10224107A1 (de) * 2002-05-29 2003-12-11 Gruenenthal Gmbh Kombination ausgewählter Opioide mit anderen Wirkstoffen zur Therapie der Harninkontinenz
DE10315878B4 (de) 2003-04-08 2009-06-04 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Fesoterodin und Verwendung

Also Published As

Publication number Publication date
TW201336491A (zh) 2013-09-16
CR10494A (es) 2009-01-19
EP2029134B1 (en) 2011-07-27
CN101466371A (zh) 2009-06-24
IL195732A0 (en) 2009-09-01
TWI397409B (zh) 2013-06-01
JP4743321B2 (ja) 2011-08-10
RS51973B (en) 2012-02-29
AP2008004673A0 (en) 2008-12-31
ECSP089010A (es) 2009-01-30
EA015909B9 (ru) 2012-03-30
NZ572616A (en) 2010-11-26
WO2007141298A1 (en) 2007-12-13
EA200802444A1 (ru) 2009-06-30
CU20080235A7 (es) 2011-04-26
KR101316773B1 (ko) 2013-10-15
HRP20110776T1 (hr) 2011-11-30
JP2011140498A (ja) 2011-07-21
ZA200806411B (en) 2009-05-27
AU2007255408B2 (en) 2013-03-14
NL2000690A1 (nl) 2007-12-11
ES2370943T3 (es) 2011-12-23
NL2000690C2 (nl) 2008-04-01
CA2652712A1 (en) 2007-12-13
IL195732A (en) 2013-09-30
NI200800318A (es) 2011-01-12
AU2007255408A1 (en) 2007-12-13
PL2029134T3 (pl) 2011-12-30
BRPI0712865B1 (pt) 2021-08-17
ATE517619T1 (de) 2011-08-15
EA015909B1 (ru) 2011-12-30
JP4781489B2 (ja) 2011-09-28
NO341980B1 (no) 2018-03-05
PE20080331A1 (es) 2008-06-19
CA2652712C (en) 2014-04-01
MA30504B1 (fr) 2009-06-01
CY1111934T1 (el) 2015-11-04
JP2009539802A (ja) 2009-11-19
SI2029134T1 (sl) 2012-01-31
HK1128626A1 (en) 2009-11-06
PE20120476A1 (es) 2012-04-20
GT200800276A (es) 2009-06-18
TWI520735B (zh) 2016-02-11
MX2008015736A (es) 2009-01-09
TW200814992A (en) 2008-04-01
AP2416A (en) 2012-06-01
PT2029134E (pt) 2011-11-02
DK2029134T3 (da) 2011-10-17
KR20090026135A (ko) 2009-03-11
AR061289A1 (es) 2008-08-20
MY146574A (en) 2012-08-30
CN101466371B (zh) 2011-10-05
BRPI0712865A2 (pt) 2012-12-18
EP2029134A1 (en) 2009-03-04
NO20090141L (no) 2009-01-09
IL220800A (en) 2015-03-31
TNSN08505A1 (fr) 2010-04-14
CU23850B1 (es) 2012-10-15

Similar Documents

Publication Publication Date Title
UY30394A1 (es) Composiciones farmacéuticas estabilizadas que comprenden fesoterodina
DK2068822T4 (da) Selvpræserverede vandige farmaceutiske sammensætninger
CL2008000789A1 (es) Compuestos derivados de adenina; composicion farmaceutica que comprende a dichos compuestos, utiles para tratar enfermedades alergicas, virales o cancer, entre otras.
NO20084368L (no) Stabile emulsjonsformuleringer
BRPI0815170A2 (pt) Composição farmacêutica que compreende um inibidor de sglt 2
DK2068839T3 (da) Farmaceutiske sammensætninger omfattende nilotinib eller salt deraf
BRPI0715712A2 (pt) Composição farmacêutica
DK1931310T3 (da) Monofasisk filmdannende sammensætning til topisk administration
BRPI0719393A2 (pt) Composição farmacêutica
BRPI0716445A2 (pt) composiÇço farmacÊutica
ZA200901702B (en) Self-preserved aqueous pharmaceutical compositions
CL2007003636A1 (es) Compuestos derivados de benzoimidazol sustituidos con sulfonilfenil; proceso para preparar dichos compuestos; composicion farmaceutica que comprenden dichos compuestos; y su uso para tratar el dolor cronico o agudo, debido a una enfermedad que causa
CL2007002315A1 (es) Compuestos derivados de piridina;composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en enfermedades o trastornos que comprenden el dolor y/o sindrome del intestino irritable.
ZA200901164B (en) Self preserved aqueous pharmaceutical compositions
CL2007000485A1 (es) Sal de alisquereno; procedimiento de preparacion; composicion farmaceutica que comprende a dicha sal; y uso del compuesto para el tratamiento de enfermedades que puedan ser moduladas mediante la inhibicion de la renina.
ATE533477T1 (de) Pharmazeutische zusammensetzungen enthaltend irbesartan
BRPI0713343A2 (pt) Composições farmacêuticas contendo anticorpo monoclonal anti-idiolípico anti-ca-125 e alumínio
DOP2008000067A (es) Composiciones farmaceuticas estabilizada que comprenden fesoterodina.
UA94107C2 (ru) Стабилизированная фармацевтическая композиция фезотеродина
CR20140109S (es) Composiciones farmaceuticas estabilizadoras que comprenden fesoterodina
GT200600132A (es) Una oxindoloxazolidinona como agente antibacteriano
AR072313A2 (es) Compuesto de azaheterociclilo biciclico sustituido, su uso para preparar un medicamento para inhibir la proteasa hcv y composiciones farmaceuticas que lo comprenden.
ITMI20061734A1 (it) Composizione farmaceutica
ITRC20060024A1 (it) Composizione farmaceutica

Legal Events

Date Code Title Description
110 Patent granted

Effective date: 20190423